Metabolic hydroxylation of 1-methyl-1,2,3,4-tetrahydro-beta-carboline in humans

Discovery of Highly Potent Serotonin 5-HT2 Receptor Agonists Inspired by Heteroyohimbine Natural Products

The serotonin 5-HT2 receptors are important pharmaceutical targets involved in signaling pathways underlying various neurological, psychiatric, and cardiac functions and dysfunctions. As such, numerous ligands for the investigation of these receptors' activity and downstream effects have been developed synthetically or discovered in nature. For example, the heteroyohimbine natural product alstonine exhibits antispychotic activity mediated by 5-HT2A/2C agonism. In this work, we identified a heteroyohimbine metabolite containing a serotonin pharmacophore and truncated the scaffold, leading to the discovery of potent agonist activity of substituted tetrahydro-β-carbolines across the 5-HT2 receptor family. Extensive SAR development resulted in compound 106 with EC50 values of 1.7, 0.58, and 0.50 nM at 5-HT2A, 5-HT2B, and 5-HT2C, respectively. Docking studies suggest a π-stacking interaction between the tetrahydro-β-carboline core and conserved residue Trp6.48 as the structural basis for this activity. This work lays a foundation for future investigation of these compounds in neurological and psychiatric disorders.

Comparative effects of β-carbolines on platelet aggregation and lipid membranes

The effects of 14 β-carbolines on human platelet aggregability were comparatively studied, and the effects on lipid membranes were determined. Several β-carbolines inhibited platelet aggregation induced by collagen, epinephrine, adenosine 5'-diphosphate, platelet-activating factor and thrombin. This activity was structure-dependent. Of all the compounds examined, 1-methyl-1,2,3,4-tetrahydro-β-carboline was the most potent. Treatment with 15-177 μM 1-methyl-1,2,3,4-tetrahydro-β-carboline inhibited the aggregation responses to different stimulants by up to 50%. Its potency was comparable to or greater than that of the antiplatelet reference, aspirin. The next most effective compound was 1-methyl-3,4-dihydro-β-carboline. The structure-antiplatelet activity relationship indicated that this activity is reduced by oxidation to 1-methyl-β-carboline, by demethylation to 1,2,3,4-tetrahydro-β-carboline and by 6-hydroxylation, 7-hydroxylation and 3-carboxylation. Active 1-methyl-1,2,3,4-tetrahydro-β-carboline fluidized biomimetic membranes at 25-250 μM which corresponded to the antiaggregatory concentrations, although relatively inactive 6-hydroxy-1-methyl-1,2,3,4-tetrahydro-β-carboline showed no significant effects on the membranes. β-Carbolines are considered to be effective antiplatelet agents that inhibit human platelet aggregation by interacting with lipid membranes to modify fluidity.

Indolealkylamines: biotransformations and potential drug-drug interactions

Indolealkylamine (IAA) drugs are 5-hydroxytryptamine (5-HT or serotonin) analogs that mainly act on the serotonin system. Some IAAs are clinically utilized for antimigraine therapy, whereas other substances are notable as drugs of abuse. In the clinical evaluation of antimigraine triptan drugs, studies on their biotransformations and pharmacokinetics would facilitate the understanding and prevention of unwanted drug-drug interactions (DDIs). A stable, principal metabolite of an IAA drug of abuse could serve as a useful biomarker in assessing intoxication of the IAA substance. Studies on the metabolism of IAA drugs of abuse including lysergic acid amides, tryptamine derivatives and beta-carbolines are therefore emerging. An important role for polymorphic cytochrome P450 2D6 (CYP2D6) in the metabolism of IAA drugs of abuse has been revealed by recent studies, suggesting that variations in IAA metabolism, pharmaco- or toxicokinetics and dynamics can arise from distinct CYP2D6 status, and CYP2D6 polymorphism may represent an additional risk factor in the use of these IAA drugs. Furthermore, DDIs with IAA agents could occur additively at the pharmaco/toxicokinetic and dynamic levels, leading to severe or even fatal serotonin toxicity. In this review, the metabolism and potential DDIs of these therapeutic and abused IAA drugs are described.

Biphasic effects of acetaldehyde-biogenic amine condensation products on membrane fluidity

I have studied the effects of four acetaldehyde-biogenic amine condensation products on membrane fluidity of liposomes, consisting of 1-palmitoyl-2-oleoylphosphatidylcholine and cholesterol, by measuring fluorescence polarization using different probes. The condensation products were 1-methyl-1,2,3,4-tetrahydro-beta-carboline (MTBC), 6-hydroxy-1-methyl-1,2,3,4-tetrahydro-beta-carboline (6-OH-MTBC), 3-carboxy-1-methyl-1,2,3,4-tetrahydro-beta-carboline (3-C-MTBC) and 6,7-dihydroxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (salsolinol). They changed the fluidity of the hydrophobic and hydrophilic regions of liposomal membranes at micromolar levels almost corresponding to their antibacterial and antiplatelet concentrations, but their membrane effects varied by structure, concentration and membrane lipid composition. MTBC and salsolinol showed biphasic effects on the inner layers of membranes to enhance the fluidity at 250-1000 microM and reduce the fluidity at 50-100 microM, whereas both of them fluidized the outer layers of the membranes. 3-C-MTBC concentration-dependently fluidized both layers of membranes. 6-OH-MTBC most weakly enhanced and reduced the fluidity of the outer and inner layers, respectively. The membrane effect of MTBC was the greatest of the four condensation products. MTBC (50-1000 nM) significantly reduced the fluidity by exclusively acting on the membrane core, but was less effective in fluidizing the membrane surface. However, the others were not active at low nanomolar levels. The membrane effects may be partly responsible for the antibacterial and antiplatelet actions of the acetaldehyde-biogenic amine condensation products, although they do not appear to be simple membrane fluidizers.

A possible link between beta -carboline metabolism and infantile autism

Benzodiazepine receptors and abnormal hepatic metabolism have been suggested to participate in several neuropsychiatric disorders including autism. Neuropsychoactive beta-carboline alkaloids as the potent ligands for benzodiazepine receptors are endogenously produced and exogenously supplied much more than benzodiazepines. 1-Methyl-1,2,3,4-tetrahydro-beta-carboline, a predominant alkaloid in humans and foodstuffs, is metabolically hydroxylated in liver. Although its in vivo levels show no difference between autistic and healthy children, the metabolic 6-hydroxylation is significantly decreased in autistic subjects. Therefore, it could be hypothesized that the reduced hepatic metabolism of 1-methyl-1,2,3, 4-tetrahydro-beta-carboline to 6-hydroxyl metabolite may be linked to the pathogenesis of infantile autism as suggested for autistic occurrence to involve the pathology similar to hepatic encephalopathy.